Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)
India · Delayed Price · Currency is INR | Market Cap | 1.24B -46.6% |
| Revenue (ttm) | 230.23M -53.2% |
| Net Income | -228.62M |
| EPS | -10.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,837 |
| Average Volume | 12,024 |
| Open | 59.12 |
| Previous Close | 59.49 |
| Day's Range | 59.00 - 61.28 |
| 52-Week Range | 53.05 - 113.50 |
| Beta | 0.23 |
| RSI | 47.95 |
| Earnings Date | Feb 9, 2026 |
About NSE:KREBSBIO
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity... [Read more]
Financial Performance
In fiscal year 2025, NSE:KREBSBIO's revenue was 433.12 million, a decrease of -14.10% compared to the previous year's 504.22 million. Losses were -269.39 million, 36.6% more than in 2024.
Financial StatementsNews
Krebs Biochemicals & Industries halts production following order from Andhra Pradesh Pollution Control Board
Krebs Biochemicals & Industries Limited announced that it has been directed to immediately cease all production activities at its manufacturing unit located in Kothapalli (V), Kasimkota (M), Anakapall...